Effects of an angiotensin-converting enzyme inhibitor on the inflammatory response in in vivo and in vitro models

Critical Care Medicine

Volumn 37, Issue 2, 2009, Pages 626-633

  Hagiwara, Satoshi ^a   Iwasaka, Hideo ^a   Matumoto, Shigekiyo ^a   Hidaka, Seigo ^a   Noguchi, Takayuki ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Acute lung injury; Enalapril; High mobility group box 1; Lipopolysaccharides

Indexed keywords

ANGIOTENSIN II; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HIGH MOBILITY GROUP B1 PROTEIN; I KAPPA B; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DRUG EFFECT; ENDOTOXEMIA; EXPERIMENTAL MODEL; EXPERIMENTAL RAT; HISTOLOGY; HISTOPATHOLOGY; HYPERTENSION; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; INTERSTITIAL FLUID; LUNG CONGESTION; LUNG EDEMA; LUNG HEMORRHAGE; LUNG PARENCHYMA; MALE; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; RAT; SEPSIS; WISTAR RAT;

ACUTE LUNG INJURY; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CELL LINE; CYTOKINES; ENALAPRIL; HMGB1 PROTEIN; LIPOPOLYSACCHARIDES; MALE; MICE; RANDOM ALLOCATION; RATS; RATS, WISTAR; SEPSIS;

EID: 67650361681     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181958d91     Document Type: Article

References (45)

1. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554
2. Wyncoll DL, Evans TW: Acute respiratory distress syndrome. Lancet 1999; 354: 497-501
3. Lehr HA, Bittinger F, Kirkpatrick CJ: Microcirculatory dysfunction in sepsis: A pathogenetic basis for therapy? J Pathol 2000; 190: 373-386
4. Riedemann NC, Guo RF, Ward PA: The enigma of sepsis. J Clin Invest 2003; 112: 460-467
5. Wang H, Yang H, Czura CJ, et al: HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 2001; 164: 1768-1773
6. Bustin M: Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 1999; 19:5237-5246
7. Wang H, Vishnubhakat JM, Bloom O, et al: Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 1999; 126:389-392
8. Wang H, Bloom O, Zhang M, et al: HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285:248-251
9. Abd el-Aziz MA, Othman AI, Amer M, et al: Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats. J Appl Toxicol 2001; 21:469-473
10. Griffin KA, Abu-Amarah I, Picken M, et al: Renoprotection by ACE inhibition or aldosterone blockade is blood pressure-dependent. Hypertension 2003; 41:201-206
11. Stojiljkovic L, Behnia R: Role of renin angiotensin system inhibitors in cardiovascular and renal protection: A lesson from clinical trials. Curr Pharm Des 2007; 13:1335-1345
12. Suzuki Y, Ruiz-Ortega M, Lorenzo O, et al: Inflammation and angiotensin II. Int J Biochem Cell Biol 2003; 35:881-900
13. Idell S, Kueppers F, Lippmann M, et al: Angiotensin converting enzyme in bronchoal-veolar lavage in ARDS. Chest 1987; 91:52-56
14. Jerng JS, Yu CJ, Wang HC, et al: Polymorphism of the angiotensin- converting enzyme gene affects the outcome of acute respiratory distress syndrome. Crit Care Med 2006; 34: 1001-1006
15. Imai Y, Kuba K, Rao S, et al: Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005; 436: 112-116
16. Murakami K, McGuire R, Cox RA, et al: Heparin nebulization attenuates acute lung injury in sepsis following smoke inhalation in sheep. Shock 2002; 18:236-241
17. Koike K, Moore FA, Moore EE, et al: Endotoxin after gut ischemia/reperfusion causes irreversible lung injury. J Surg Res 1992; 52:656-662
18. Zhang H, Sun GY: LPS induces permeability injury in lung microvascular endothelium via AT(1) receptor. Arch Biochem Biophys 2005; 441:75-83
19. Cavaillon JM, Adib-Conquy M: Monocytes/ macrophages and sepsis. Crit Care Med 2005; 33(Suppl 12):S506-S509
20. Phillips MI, Kagiyama S: Angiotensin II as a pro-inflammatory mediator. Curr Opin Investig Drugs 2002; 3:569-577
21. Tham DM, Martin-McNulty B, Wang YX, et al: Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol Genomics 2002; 11:21-30
22. Esteban V, Ruperez M, Vita JR, et al: Effect of simultaneous blockade of AT1 and AT2 receptors on the NFkappaB pathway and renal inflammatory response. Kidney Int Suppl 2003; 86:S33-S38
23. Koyuncuoǧlu H, Güngör M, Hatipoǧlu I, et al: Changes in brain and lung angiotensin converting enzyme activity in various shocks. Pharmacol Res Commun 1984; 16: 479-484
24. Wösten-van Asperen RM, Lutter R, Haitsma JJ, et al: ACE mediates ventilator-induced lung injury in rats via angiotensin II but not bradykinin. Eur Respir J 2008; 31:363-371
25. Jerng JS, Hsu YC, Wu HD, et al: Role of the renin-angiotensin system in ventilator-induced lung injury: An in vivo study in a rat model. Thorax 2007; 62:527-535
26. Kuba K, Imai Y, Rao S, et al: A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005; 11:875-879
27. Zhao Y, Chen X, Cai L, et al: Angiotensin II suppresses adriamycin-induced apoptosis through activation of phosphatidylinositol 3-kinase/Akt signaling in human breast cancer cells. Acta Biochim Biophys Sin (Shanghai) 2008; 40:304-310
28. Miyoshi M, Miyano K, Moriyama N, et al: Angiotensin type 1 receptor antagonist inhibits lipopolysaccharide-induced stimulation of rat microglial cells by suppressing nuclear factor kappaB and activator protein-1 activation. Eur J Neurosci 2008; 27: 343-351
29. Yayama K, Okamoto H: Angiotensin II-induced vasodilation via type 2 receptor: Role of bradykinin and nitric oxide. Int Immunopharmacol 2008; 8:312-318
30. Sriskandan S, Altmann DM: The immunology of sepsis. J Pathol 2008; 214:211-223
31. Fink MP: Therapeutic options directed against platelet activating factor, eicosanoids and bradykinin in sepsis. J Antimicrob Chemother 1998; 41(Suppl A):81-94
32. Matsuda N, Hattori Y: Systemic inflammatory response syndrome (SIRS): Molecular pathophysiology and gene therapy. J Pharmacol Sci 2006; 101:189-198
33. Li Q, Verma IM: NF-kappaB regulation in the immune system. Nat Rev Immunol 2002; 2:725-734
34. Liu SF, Malik AB: NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 2006; 290:622-645
35. Zingarelli B, Sheehan M, Wong HR: Nuclear factor-kappaB as a therapeutic target in critical care medicine. Crit Care Med 2003; 31: 105-111
36. Park JS, Arcaroli J, Yum HK, et al: Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol 2003; 284:C870-C879
37. Guha M, Mackman N: LPS induction of gene expression in human monocytes. Cell Signal 2001; 13:85-94
38. Kwak HJ, Song JS, Heo JY, et al: Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation. J Pharmacol Exp Ther 2005; 315: 1188-1195
39. Schottelius AJ, Mayo MW, Sartor RB, et al: Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 1999; 274: 31868-31874
40. Bhatia M, Moochhala S: Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. J Pathol 2004; 202:145-156
41. Strieter RM, Kunkel SL, Bone RC: Role of tumor necrosis factor-α in disease states and inflammation. Crit Care Med 1993; 21: S447-S463
42. Remick DG, Bolgos GR, Siddiqui J, et al: Interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 2002; 17:463-467
43. Abraham E, Arcaroli J, Carmody A, et al: HMG-1 as a mediator of acute lung inflammation. J Immunol 2000; 165:2950-2954
44. Ueno H, Matsuda T, Hashimoto S, et al: Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 2004; 170: 1310-1316
45. Wang H, Yang H, Tracey KJ: Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med 2004; 255:320-331